Microbot Medical, which is a pre-clinical medical device company, recently announced that it has received a Notice of Allowance for one of its Patent Applications from Israel Intellectual Property Office. The recently granted patent whose patent application number is 231815 pertains to a system to reduce shunt stenosis. Intended to continue diversifying and expanding its Intellectual Property (IP) portfolio, Microbot has filed numerous patent applications. And now, after getting the latest Notice of Allowance, the company holds 33 issued patents and 18 pending patent applications globally.
The co-founder of Microbot Medical, HarelGadot, explained that one of their objectives is to leverage their advanced robotic technologies and explore the opportunities to get the most out of the market. The present dialysis market is available with an alternative to the existing standard of care and an umbrella full of market opportunities for their self-cleaning dialysis shunts. The allowed patent empowers them to expand and safeguard the product offerings they will be bringing in the future while assuring sustainable competitive advantages. They have faith that their firm will increase the patients’ benefits while decreasing the healthcare costs as shunt occlusion is a common complication.
The system mentioned in the patent emphasizes lessening venous stenosis related to the usage of hemodialysis shunts. The process that pertains to this system starts by inserting a cleaning device into the patient’s blood vessel. There are two needle bores, out of which the first one is set to be removed later on, while the second one is set to return the purified blood into the blood vessel.
The clearing device, when in use, contacts with the walls of the blood vessel and acts as a passive device moved down the blood vessel by the flow of blood or an autonomous crawling device, like the TipCatTM device of the company.
As per the USRDS (U.S. Renal Data System), around 750,000 patients in the United States and 2 million patients worldwide get affected by the end-stage renal disease (ESRD) per year. With the continuous increase in the number of patients incurring with the same disorder, dialysis appears the only alternative to kidney transplantation in today’s time.
Dialysis, also known as hemodialysis, refers to a process of purifying the blood of the patient suffering from kidney failure. The process emphasizes using an external circuit to pump the victim’s blood for filtering before it returns into the body. A typical hemodialysis is scheduled for three sessions per week, and each session is of 3-5 hours. For
view source: https://www.kashishipr.com/blog/microbot-medical-obtains-notice-of-allowance-for-a-new-patent/
Don’t forget to follow us on social media:
Facebook – https://www.facebook.com/trademarkmaldives/
Twitter – https://twitter.com/trademarkmaldiv
Pinterest – https://in.pinterest.com/trademarkmaldives/
No comments:
Post a Comment